The Cancer Letter

Inside information on cancer research and drug development

Vol.
28
No.
7
February 15, 2002Feb 15, 2002
Free
DOWNLOAD THE PDF

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

ImClone Protocol Generates More Questions Than Answers.

Phase III Trial Would Give Clearer Picture Of C225 Role.

Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.

Levine Leaves Presidency Of Rockefeller University.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account